– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...

Carcinoid syndrome is a rare condition typically affecting people with advanced carcinoid tumors. These rare, slow-growing tumors affect hormone-releasing neuroendocrine cells. The tumors can ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the ...

nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

Positive Phase 2 data for Paltusotine in carcinoid syndrome and Atumelnant ... glucagon) and tumor growth suppression in neuroendocrine tumors (NETs). As I noted before: In acromegaly, currently ...

and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a ...

and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a ...

Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic ...

“The characteristics of NET vary widely from patient to patient, and very few treatment options have demonstrated the ability to improve outcomes across such a heterogeneous population,” said Jennifer ...